Addressing Cognitive Impairment in Heart Failure Management: Insights from HFSA Scientific Statement

Explore the latest insights into cognitive impairment's impact on heart failure management in this in-depth discussion featuring Eiran Gorodeski, MD, MPH, Parag Goyal, MD, MS, and James Fang, MD. Published on March 12, 2024, by the Heart Failure Society of America (HFSA), their scientific statement delves into risk factors, implications, and management strategies for cognitive impairment in heart failure patients. With the aging US population fueling concerns about rising heart failure prevalence, understanding cognitive impairment's role is crucial for effective patient care.

In this peer-to-peer dialogue hosted by HCPLive, Dr. Fang, HFSA President, moderates a conversation with Drs. Gorodeski and Goyal, lead co-authors of the statement. Together, they explore key insights, recommended screening tools, and challenges in implementing changes based on contemporary literature. As fellowship slots in heart failure remain unfilled, the discussion sheds light on the urgent need for proactive management strategies to address this looming public health challenge.

Stay informed and join the conversation on advancing heart failure management amidst the complexities of cognitive impairment. Subscribe now for more updates and expert discussions on the latest in cardiovascular health from HCPLive.

Discussion Guests:

Eiran Gorodeski, MD, MPH, director of the Advanced Heart Failure & Transplant Center at Harrington Heart & Vascular Institute in the University Hospitals Health System as well as section head of advanced heart failure in the Division of Cardiovascular Medicine and Professor of Medicine at Case Western Reserve University.

Parag Goyal, MD, MSc, statement co-author, associate professor of Medicine, the Founding Director of the Heart Failure with Preserved Ejection Fraction Program, and the director of the Cardiac Amyloidosis Program at Weill Cornell Medicine.

James Fang, MD, president of the Heart Failure Society of America, chief of Cardiovascular Medicine at the University of Utah School of Medicine, and director of the Cardiovascular Service Line at University of Utah Health Care.

Relevant disclosures for Gorodeski include Dynamed Plus. Relevant disclosures for Goyal include Agepha, Axon, and Sensorum Health. Relevant disclosures for Fang include Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, and others.

References:

Bozkurt B, Ahmad T, Alexander KM, et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412-1451. doi:10.1016/j.cardfail.2023.07.006
Goyal P, DiDomenico RJ, Pressler SJ, Allen LA, Gorodeski EZ. Cognitive Impairment in Heart Failure: A Heart Failure Society of America Scientific Statement. Journal of Cardiac Failure. Published online March 12, 2024. doi:10.1016/j.cardfail.2024.01.003

Learn more: https://www.hcplive.com/view/the-role...